Short sellers have raised bearish bets on PFE by 14% over the past month. Analyst opinion remains split, with targets averaging 7% upside but recent downgrades tempering optimism.
Short interest stands at 136.8 million shares as of April 23, representing 2.41% of the free float. That marks a 3.0% increase over the past week and a 14% jump over the past month. Days to cover sits at 3.99 based on the latest official FINRA data. Cost to borrow remains negligible at 0.41%, down 9.5% week-over-week. Utilisation has climbed to 0.99%, its highest level since early April, though still well below the 52-week peak of 3.79%.
Put/call ratio closed at 0.87 on April 24, above the 20-day mean of 0.85. The z-score of 1.67 signals moderately elevated hedging demand. PCR sits in the upper half of its 52-week range (0.64–1.05), suggesting mildly defensive positioning heading into the print.
The Street maintains a consensus price target of $28.93, implying 7% upside from the current $27.00 price. Recent moves show divergence. CICC initiated coverage at Outperform with a $33 target on April 16. Guggenheim raised its Buy-rated target to $36 on March 24, and HSBC lifted its target to $32 on March 17. On the bearish side, RBC Capital reiterated Underperform at $25 on April 20, and B of A Securities cut its Neutral target from $27 to $26 on April 9. Benzinga's bull case points to Pfizer's $60 billion annual sales run-rate and diversified portfolio, led by Prevnar 13, Ibrance, and Eliquis. The bear case flags anticipated gross-to-net adjustments on Vyndaqel and Ibrance that may weigh on near-term revenue recognition.
P/E sits at 9.14, down 0.17 points over the past 30 days. EV/EBITDA stands at 8.22, up marginally from a month ago. The stock ranks in the 98th percentile on 12-month forward EPS growth expectations and the 92nd percentile on analyst recommendation divergence. Momentum and quality scores are unavailable.
Insiders sold $21.1 million net over the past 90 days, led by CEO Albert Bourla's $12.6 million sale on February 25. BlackRock holds 8.7% of shares outstanding, adding 241,000 shares in the March quarter.
Pfizer last reported on February 3. Prior prints occurred in late 2025. The stock has drifted 2% lower over the past week despite a 1.2% gain on April 24.
No active ORTEX Alpha signals.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
